New Patent Cover IL-23R Orally Stable Peptide Inhibitors Including Protagonist’s PTG-200 to Treat IBD

New Patent Cover IL-23R Orally Stable Peptide Inhibitors Including Protagonist’s PTG-200 to Treat IBD
Protagonist Therapeutics has secured a patent covering orally stable peptide inhibitors of the interleukin-23 receptor (IL-23R), including its lead candidate drug PTG-200. The patent protects PTG-200’s formulation as well the use of this class of inhibitors to treat inflammatory bowel disease (IBD). The patent provides intellectual property coverage until 2035, David Liu, Protagonist’s chief scientific officer and head

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *